STOCK TITAN

Axogen (AXGN) Stock Price, News & Analysis

AXGN NASDAQ
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
28 252 sessions, November 13, 2025 to November 13, 2026
Largest daily move
+31.5% close of October 28, 2026
1-year change
+132.7% closing prices, November 13, 2025 to November 13, 2026
1-month change
+54.6% closing prices, October 13, 2026 to November 13, 2026

Company Description

Axogen, Inc. (NASDAQ: AXGN) is a medical technology company focused on the science, development, and commercialization of technologies for peripheral nerve repair, regeneration, and restoration of function. According to the company’s disclosures, its mission is to make restoration of peripheral nerve function an expected standard of care by advancing research, education, and collaboration with surgeons and healthcare providers across a global network.

Axogen is incorporated in Minnesota and its common stock trades on The Nasdaq Stock Market under the symbol AXGN. The company describes itself as a global leader in developing and marketing surgical solutions for the restoration of peripheral nerve function. Peripheral nerves provide pathways for motor and sensory signals throughout the body, and Axogen highlights that damage to these nerves or failure to reconnect them properly can result in loss of muscle or organ function, loss of sensation, or pain.

Peripheral nerve repair focus

Axogen concentrates specifically on peripheral nerve injuries and related surgical procedures. Its platform for peripheral nerve repair is used in traumatic injuries and in a range of scheduled and emergent procedures. The company notes applications in extremity trauma, oral and maxillofacial surgery, head and neck procedures, breast reconstruction, and the surgical treatment of pain, including neuroma management and nerve decompression.

In scheduled procedures, Axogen’s products are used for patients seeking relief from conditions caused by nerve defects or prior surgical interventions, such as regaining sensation after breast reconstruction following mastectomy or reconstructing nerves after removal of painful neuromas. In emergent settings, its products are used when injuries present in emergency departments and specialists intervene soon after the initial trauma.

Product portfolio

Axogen reports a portfolio of products designed for different aspects of peripheral nerve repair and protection:

  • Avance® Nerve Graft / Avance® (acellular nerve allograft-arwx) – a processed human nerve allograft described as an acellular nerve scaffold for bridging severed peripheral nerves. It is indicated for adult and pediatric patients aged one month and older with sensory, mixed, and motor peripheral nerve discontinuities. The company notes that Avance has been approved by the U.S. Food and Drug Administration (FDA) as a biologic therapeutic option for treating peripheral nerve discontinuities, with certain indications approved under the FDA’s Accelerated Approval pathway based on static two-point discrimination outcomes.
  • Axoguard Nerve Connector® – a porcine submucosa extracellular matrix (ECM) coaptation aid used for tensionless repair of severed peripheral nerves.
  • Axoguard Nerve Protector® – a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while minimizing or preventing soft tissue attachments.
  • Axoguard HA+ Nerve Protector™ – a porcine submucosa ECM base layer coated with a proprietary hyaluronate–alginate gel, described as a next-generation technology designed to enhance nerve gliding and provide short- and long-term protection for peripheral nerve injuries.
  • Axoguard Nerve Cap® – a porcine submucosa ECM product used to protect a peripheral nerve end and separate it from surrounding tissue to reduce the development of symptomatic or painful neuroma.
  • Avive+ Soft Tissue Matrix™ – a multi-layer amniotic membrane allograft used to protect and separate tissues in the surgical bed during the critical phase of tissue healing or repair.

The company states that its portfolio is intended to offer repair options across the spectrum of peripheral nerve injuries, from bridging nerve gaps to protecting nerve reconstruction sites and managing nerve ends associated with pain.

Regulatory and clinical context for Avance

Axogen has highlighted a significant regulatory milestone with FDA approval of the Biologics License Application (BLA) for Avance® (acellular nerve allograft-arwx). According to the company’s press releases and related SEC filings, Avance is indicated for treatment of sensory, mixed, and motor peripheral nerve discontinuities in patients aged one month and older. The indications for sensory nerve discontinuities greater than 25 mm and for mixed and motor nerve discontinuities were approved under the FDA’s Accelerated Approval pathway, based on static two-point discrimination in sensory nerve gaps of 25 mm or less. Continued approval for these indications depends on verification and description of clinical benefit in confirmatory studies.

Axogen notes that Avance had historically been classified as a human tissue product, and that BLA approval transitions it to a biologic regulatory framework. The company states that this approval clarifies and strengthens its regulatory footing and confirms Avance as an acceptable therapeutic option for treating peripheral nerve discontinuities in its current nerve repair use cases.

Clinical and market development

Axogen emphasizes its role in market development for peripheral nerve repair. The company cites position statements and clinical practice guidelines from professional societies, including the American Association of Hand Surgery (AAHS), the American Society for Reconstructive Microsurgery (ASRM), and the American Association of Oral and Maxillofacial Surgeons (AAOMS), recognizing nerve allograft as a standard medical practice option for treatment of peripheral nerve defects. Axogen also reports expanded coverage and reimbursement for nerve repair using synthetic conduits or allografts among commercial payers.

Through research, education, and collaboration with surgeons and healthcare providers, Axogen describes efforts to increase utilization of its peripheral nerve surgical algorithm across procedures and to expand adoption in extremities, oral and maxillofacial, head and neck, breast reconstruction (including Resensation® in post-mastectomy breast reconstruction), and surgical treatment of pain.

Geographic reach

According to the company’s disclosures, the Axogen portfolio of products is available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. Other company communications also refer to availability in additional European and international markets.

Corporate and shareholder information

Axogen, Inc. is organized under the laws of Minnesota and lists its common stock, with a par value of $0.01 per share, on The Nasdaq Stock Market under the ticker AXGN. The company files periodic reports, current reports, and other documents with the U.S. Securities and Exchange Commission (SEC), including Forms 10-K, 10-Q, and 8-K, which provide details on financial performance, risk factors, regulatory milestones, and corporate governance matters such as annual shareholder meeting results and executive compensation arrangements.

Axogen also reports using non-GAAP financial measures such as EBITDA, Adjusted EBITDA, Adjusted Net Income (Loss), and related margins for internal decision-making and for evaluating period-to-period performance, in addition to financial measures prepared in accordance with U.S. GAAP.

Risk and regulatory considerations

The company’s forward-looking statements highlight factors that may affect its business, including product development timelines, regulatory processes and approvals, surgeon and product adoption rates, market awareness, reimbursement coverage, macroeconomic conditions, and geopolitical events. Axogen notes that forward-looking statements are not guarantees of future performance and refers investors to the risk factors described in its Annual Report on Form 10-K and other SEC filings.

Summary

In summary, Axogen, Inc. is a Nasdaq-listed medical technology company focused on peripheral nerve repair and regeneration. It offers a defined portfolio of nerve allografts, ECM-based nerve protection and coaptation products, and soft tissue matrices used across traumatic and reconstructive procedures. The company emphasizes its mission to restore health and improve quality of life by making restoration of peripheral nerve function an expected standard of care, supported by regulatory milestones, clinical evidence, and engagement with surgical specialties and payers.

Stock Performance

$55.50
-0.77%
-0.43
After hoursChange vs the $55.93 closeLast updated: November 13, 2026 at 16:42
+132.7%
Performance 1 year

Axogen (AXGN) closed at $55.93 on November 13, 2026. Over the past 12 months, the price has gained 132.7%.

See what a $1,000 investment in AXGN would be worth today

Average down calculator for AXGN

AXGN Metrics & Rankings

Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Insider Radar

Net Sellers
90-Day Summary
0
Shares Bought
3,500
Shares Sold
1
Transactions
Most Recent Transaction
TYNDALL JOSEPH A. (Director) sold 3,500 shares @ $49.70 on September 2, 2026

Insider selling at Axogen over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.

Based on SEC Form 4 filings over the last 90 days.

Financial Highlights

Axogen generated $225.2M in revenue in FY2025, retaining a 74.3% gross margin, operating income reached -$7.8M (-3.5% operating margin), and net income was -$15.7M, reflecting a -7.0% net profit margin. Diluted earnings per share stood at -$0.34. The company generated $812K in operating cash flow. The current ratio was 5.11, measuring current assets divided by current liabilities.

$225.2M
Revenue (FY2025)
-$15.7M
Net Income (FY2025)
$812K
Operating Cash Flow

Upcoming Events

NOV
17
November 17, 2026 Marketing

Jefferies Fireside Chat

Fireside chat at Jefferies conference in London on Nov 17 at 8:30 AM ET; includes one-on-one investor meetings; conference appearance.
DEC
02
December 2, 2026 Marketing

Piper Sandler Presentation

Presentation at Piper Sandler conference on Dec 2 at 8:00 AM ET; includes one-on-one investor meetings; investor presentation slot.
YEAR
2026
2026 Financial

Fiscal year-end

Axogen's fiscal year-end for 2026; closes period for revenue guidance of at least $290M and free cash flow target.

Axogen has 3 upcoming scheduled events. The next event, "Jefferies Fireside Chat", is scheduled for November 17, 2026 (tomorrow). 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the AXGN stock price.

Short Interest History

Last 12 Months

Short interest in Axogen (AXGN) currently stands at 7.0 million shares, up 36.5% from the previous reporting period, representing 12.0% of the float. Since November 2025, short interest has increased by 145.4%.

Days to Cover History

Last 12 Months

Days to cover for Axogen (AXGN) currently stands at 3.3 days, up 8.6% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 2.2 to 4.2 days.

AXGN Company Profile & Sector Positioning

Axogen (AXGN) operates in the Medical Devices industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing AXGN often look at related companies in the same sector, including TransMedics Group, Inc. (TMDX), iRhythm Holdings, Inc. (IRTC), Integer Holdings Corporation (ITGR), Neogen Corp (NEOG), and UFP Technologies Inc (UFPT). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate AXGN's relative position within its industry.

Frequently Asked Questions

The current stock price of Axogen (AXGN) is $55.50 in after-hours trading as of November 13, 2026.

The market cap of Axogen (AXGN) is approximately $3.3B. Learn more about what market capitalization means .

The FY2025 revenue of Axogen (AXGN) is $225.2M, from its most recent completed fiscal year.

The FY2025 net income of Axogen (AXGN) is -$15.7M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Axogen (AXGN) is -$0.34 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Axogen (AXGN) is $812K for FY2025, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Axogen (AXGN) is -7.0% for FY2025, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Axogen (AXGN) is -3.5% for FY2025, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Axogen (AXGN) is 74.3% for FY2025, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Axogen (AXGN), current assets divided by current liabilities, was 5.11 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Axogen (AXGN) is $167.4M for FY2025, its most recent completed fiscal year.

The operating income of Axogen (AXGN) is -$7.8M for FY2025, its most recent completed fiscal year. Learn about operating income.

Axogen, Inc. focuses on the science, development, and commercialization of technologies for peripheral nerve repair, regeneration, and restoration of function. Its products are used by surgeons and healthcare providers in traumatic injuries and a range of scheduled and emergent procedures involving peripheral nerves.

Avance, also referred to as Avance Nerve Graft or Avance (acellular nerve allograft-arwx), is a processed human nerve allograft described as an acellular nerve scaffold. It is indicated for adult and pediatric patients aged one month and older with sensory, mixed, and motor peripheral nerve discontinuities and is used to bridge severed peripheral nerves.

Axogen reports that its peripheral nerve repair platform is used across traumatic injuries, oral and maxillofacial surgery, head and neck procedures, breast reconstruction, and the surgical treatment of pain. These applications include both scheduled procedures, such as restoring sensation after mastectomy, and emergent procedures following acute injuries.

Axogen’s portfolio includes Avance Nerve Graft / Avance (acellular nerve allograft-arwx), Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. These products are designed for bridging nerve gaps, protecting reconstructed nerves, managing nerve ends, and separating tissues during healing.

Axogen has announced that the U.S. Food and Drug Administration approved its Biologics License Application for Avance (acellular nerve allograft-arwx). Certain indications, such as sensory nerve discontinuities greater than 25 mm and mixed and motor nerve discontinuities, were approved under the FDA’s Accelerated Approval pathway based on static two-point discrimination outcomes, with continued approval contingent on confirmatory studies.

According to company disclosures, Axogen’s products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries, as well as additional European and international markets referenced in its communications.

Axogen states that peripheral nerves provide pathways for motor and sensory signals throughout the body and that physical damage to a peripheral nerve, or failure to reconnect it properly, can lead to loss of muscle or organ function, loss of sensory feeling, or the initiation of pain. Its products are intended to provide repair options for such injuries.

The company reports that organizations such as the American Association of Hand Surgery, the American Society for Reconstructive Microsurgery, and the American Association of Oral and Maxillofacial Surgeons have issued position statements or clinical practice guidelines recognizing nerve allograft as a standard medical practice option for treating peripheral nerve defects. Axogen cites these developments as supportive of its market development strategy.

Axogen’s common stock trades on The Nasdaq Stock Market under the ticker symbol AXGN. The company is incorporated in Minnesota and files periodic and current reports with the U.S. Securities and Exchange Commission.

In addition to GAAP financial measures, Axogen reports non-GAAP metrics such as EBITDA, Adjusted EBITDA, Adjusted Net Income (Loss), and related margins. The company states that these measures are used for financial and operational decision-making and to evaluate period-to-period performance, while noting that they are not a substitute for GAAP measures.